{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2015"],"condition":["Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma","Carcinoma, Non-Small-Cell Lung"],"disease":["Non-small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma","Carcinoma, Non-small-cell Lung"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2191063"],"location":["United States"],"study_start_month":["6"],"keyword":["Ravoxertinib"],"repository":["ECRIN MDR"],"study_status":["Completed"],"additional_accession":[]},"is_claimable":false,"name":"A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors","description":"This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or metastatic solid tumors for which standard therapies either do not exist or have proven ineffective or intolerable.","dates":{"creation":"2015-06-15"},"accession":"2191063","cross_references":{"ClinicalTrials___gov":["NCT02457793"],"EU Clinical Trials Register":["2015-000092-27"]}}